User
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Inc.
2303 Lindbergh Street
Auburn, CA 95602
USA
Phone: +1 800 FOR MACS
+1 530 888 8871
Fax: +1 530 888 8925
E-Mail: macs@miltenyibiotec.com
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat. Connect with us
Orders
Phone: +1 866 811 4466
Fax: +1 877 591 1060
E-Mail: orderdesk@miltenyibiotec.com
Technical support - Research products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
Technical support - Clinical products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Neoantigens result from mutations which only occur in tumor cells but not in normal healthy tissue. As they can be presented on the surface of cancer cells they are ideal targets for highly specific and safe anti-tumor immunotherapy.
PiCoP will develop an innovative process to identify the individual patient’s tumor mutations using modern bioinformatics methods.This information will be used to timely synthesize neoantigen peptides that will be loaded on the patient's own dendritic cells. The dendritic cells "trained" in this way are then administered back into the patient where they can trigger a strong immune response against the individual tumor. This innovative therapeutic concept will be evaluated in a clinical trial with our partners at the university clinics in Rostock and Greifswald.
Rostock University Medical Center, University Medicine Greifswald and Miltenyi Biotec as coordinator
Funded by the European Regional Development Fund Mecklenburg-West Pomerania, TBI-V-1-243-VBU-085
Related documents:
